I'm not calling FF and CYP a partnership - at least not in that sense it is being emphasised. I call it a normal commercial transaction with FF supplying a product and contract services and CYP paying for it.
At least CYP managed to get a small payment for it when FF returned the rights to GvHD, although it doesn't make up for the time lost between the first licence option agreement and the hand-back. Had FF acted sooner and/or CYP conducted the trial themselves earlier and had results ready at the time CRL#1 came through... Worth more than US$5 million for shareholders.
Fact is, they haven't sold a share. One reason could be that the value of their holding is nothing more than pocket change to then anyway (they could have sold at a very good profit back in 2019, but didn't). And/or with a holding close to 5%, they still have a way of being involved in an illiquid stock if they choose to. Either way, I'm not fussed. I'm annoyed at management for not pursuing any indication in Japan after successful talks with the PMDA, especially after being told for years that this is the most straight forward route. And for many years, Cynata featured in the news on a regular basis. By now, other companies and other institutions have closed the gap in the iPSC space in Japan. Shame.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)